bioAffinity Technologies (BIAF) Return on Equity (2022 - 2026)

bioAffinity Technologies (BIAF) has 5 years of Return on Equity data on file, last reported at 0.03% in Q1 2026.

• Return on Equity for Q1 2026 came in at 0.03%, up 2.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.03% (up 2.0% YoY), and the FY2025 annual result was 0.03%, down 1.0% from the prior year.
• Return on Equity eased to 0.03% in Q1 2026 per BIAF's latest filing, from 0.02% in the prior quarter.
• Over five years, Return on Equity peaked at 0.34% in Q2 2025 and troughed at 0.05% in Q1 2025.
• A 5-year average of 0.01% and a median of 0.01% in 2024 frame the typical range for Return on Equity.
• The sharpest annual moves came in 2023 and 2025: Return on Equity fell 7 bps in 2023, then soared 36 bps in 2025.
• A 5-year view of Return on Equity shows it stood at 0.01% in 2022, then sank by 94 bps to 0.01% in 2023, then plunged by 136 bps to 0.03% in 2024, then jumped by 42 bps to 0.02% in 2025, then tumbled by 58 bps to 0.03% in 2026.
• Business Quant data shows BIAF's Return on Equity at 0.03% in Q1 2026, 0.02% in Q4 2025, and 0.04% in Q3 2025.